Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atazanavir/Fosamprenavir/Ritonavir vs Atazanavir/Saquinavir/Ritonavir in PI-Naive HIV-1 Patients
NCT00122603Phase 2Completed
- Sponsor
- ANRS
- Start
- Dec 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of fosamprenavir and saquinavir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by ANRS. Primary endpoint: Virologic success (HIV RNA < 50 copies/ml) at 16 weeks. Started Dec 2005; status: completed.
02
Drugs
fosamprenavirsaquinavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00122603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00122603.